A Phase 3 interventional study of Aprocitentan 12.5 mg and Aprocitentan 25 mg in Resistant Hypertension, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 159 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-21.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,031 studies in Hypertension with a site in United States, this one is the 218th largest by enrollment of the 1,779 interventional ones that give a count, is one of 99 that started in 2018, is one of 202 in phase 3, and was the 1,205th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,031 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 99 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 730 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,779 interventional studies, 200 across the 238 observational. Of the 1,514 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,031 have an industry lead sponsor. The 10 most frequent:
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Idorsia Pharmaceuticals Ltd. has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
143 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 143 to your calendar (.ics) → With an account.
Among the 2,031 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.
Participation in the study will be up to 68 weeks.
The study has 4 periods:
The screening period lasts between 4 and 12 weeks. It starts at the screening visit with the signing of the informed consent form (ICF) and ends the day before the participant enters the run-in period.
At least 4 weeks before the start of the run-in period, the background antihypertensive medication (except beta-blockers) of participants with a diagnosis of true resistant hypertension and having a mean trough sitting systolic blood pressure of equal to or greater than 140 mmHg measured by automated AOBPM will be standardized by switching to a fixed combination of a calcium channel blocker (amlodipine), an angiotensin receptor blocker (valsartan) and a diuretic (hydrochlorothiazide).
In case a beta-blocker is used as one of the background antihypertensive medications or for any other indication, this can be kept, with the provision that it has been initiated and the dose kept stable for at least 4 weeks prior to the screening visit and the dose kept stable until the end-of-treatment.
Following the screening period this study has a run-in period of 4 weeks. During this period, placebo will be administered in order to exclude potential placebo responders.
Following the run-in period eligible participants will enter the randomized treatment period. This period lasts for 48 weeks. It starts at randomization (i.e., Day 1 of the double-blind part) and ends at the end-of-treatment visit (i.e., at the end of the double-blind withdrawal part).
The randomized treatment period consists of 3 parts: Part 1 is double-blind, randomized, parallel-group and placebo-controlled and lasts 4 weeks. Part 2 is single-blind and single-arm and lasts for 32 weeks. Part 3 is a double-blind withdrawal, randomized, parallel-group and placebo-controlled and lasts for 12 weeks.
End-of treatment is at Week 48 (i.e., end of the double-blind withdrawal part). The safety follow-up starts on the day after the last dose of study treatment and ends 30 to 33 days after the last dose of study treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Screening period:
Women of are eligible only if the following applies:
Run-in period (RI):
Randomization period:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive aprocitentan 25 mg, orally, once daily in the morning for 4 weeks.
Drug: Aprocitentan 25 mg
Participants will receive aprocitentan 12.5 mg, orally, once daily in the morning for 4 weeks.
Drug: Aprocitentan 12.5 mg
Participants will receive placebo (matching aprocitentan), orally, once daily in the morning for 4 weeks.
Drug: Placebo
After 4-weeks in the double-blind randomized part (Part 1), participants will received 25 mg aprocitentan, orally, once daily in the morning for 32 weeks.
Drug: Aprocitentan 25 mg
After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive aprocitentan 25 mg, orally, once daily in the morning for 12 weeks.
Drug: Aprocitentan 25 mg
After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive placebo (matching aprocitentan), orally, once daily in the morning for 12 weeks.
Drug: Placebo
Tablet, oral use
Also known as: ACT-132577
Tablet, oral use
Also known as: ACT-132577
Matching placebo tablet
Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement
Changes from baseline to Week 4 in mean trough SiSBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiSBP from baseline.
Time frame: Pre-dose Day 1 (Part 1 double-blind randomized baseline) up to Week 4 (End of double-blind randomized part 1)
Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Unattended Automated Office Blood Pressure Measurement
Changes from double-blind withdrawal baseline (Week 36) to Week 40 in mean trough SiSBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiSBP from baseline.
Time frame: Pre-dose Week 36 (Part 3 double-blind-withdrawal baseline) up to Week 40
Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement
Changes from baseline to Week 4 in mean trough SiDBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. A negative change indicates a decrease in SiDBP from baseline.
Time frame: Pre-dose Day 1 (Part 1 double-blind randomized baseline) up to Week 4 (End of double-blind randomized part 1)
Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring
ABPM devices were provided to each site by the central blood pressure laboratory. On the first day after all visit assessments were performed, the ABPM device (Mobil-O-Graph NG) was fitted to the participant. The following day (i.e., second day), the participant came back to site to have the ABPM device removed. ABPM data collected over the 24-hours was electronically transferred to the central BP laboratory. Systolic blood pressure and diastolic blood pressure were measured at predetermined times every 20 minutes from 06:00 to 21:59, and every 30 minutes from 22:00 to 05:59. For each participant and at each visit (baseline and Week 4) the 24-hour mean SBP (or DBP) was calculated from the area under the SBP (or DBP) time curve and divided by the time span. A negative change indicates a decrease in 24-hour mean systolic / diastolic blood pressure from baseline.
Time frame: Pre-dose Day 1 (Part 1 double-blind randomized baseline) and Week 4 (End of double-blind randomized part 1)
Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure
Changes from double-blind withdrawal (Week 36) to Week 40 in mean trough SiDBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiDBP from baseline.
Time frame: Pre-dose Week 36 (Part 3 double-blind-withdrawal baseline) up to Week 40
Changes From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring
ABPM devices were provided to each site by the central blood pressure laboratory. On the first day after all visit assessments were performed, the ABPM device (Mobil-O-Graph NG) was fitted to the participant. The following day (i.e., second day), the participant came back to site to have the ABPM device removed. ABPM data collected over the 24-hours was electronically transferred to the central BP laboratory. Systolic blood pressure and diastolic blood pressure were measured at predetermined times every 20 minutes from 06:00 to 21:59, and every 30 minutes from 22:00 to 05:59. For each participant and at each visit (the double-blind withdrawal baseline \[Week 36\] and the week 40) the 24-hour mean SBP (or DBP) was calculated from the area under the SBP (or DBP) time curve. A negative change indicates a decrease in 24-hour mean systolic / diastolic blood pressure from baseline.
Time frame: From Week 36 (Part 3 double-blind-withdrawal baseline) and Week 40
The study was done from 18 June 2018 to 25 April 2022.
| Milestone | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 2 (Single-blind) | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | Placebo in Part 3 (Double-blind Withdrawal) |
|---|---|---|---|---|---|---|
| Started | 243 | 243 | 244 | 0 | 0 | 0 |
| Safety set | 243 | 245 | 242 | 0 | 0 | 0 |
| Completed | 232 | 234 | 238 | 0 | 0 | 0 |
| Not completed | 11 | 9 | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 6 | 5 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Other reasons | 3 | 2 | 3 | 0 | 0 | 0 |
| Milestone | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 2 (Single-blind) | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | Placebo in Part 3 (Double-blind Withdrawal) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 704 | 0 | 0 |
| Completed | 0 | 0 | 0 | 613 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 91 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 25 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 19 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 8 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 5 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 0 | 32 | 0 | 0 |
| Milestone | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 2 (Single-blind) | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | Placebo in Part 3 (Double-blind Withdrawal) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 307 | 307 |
| Safety set | 0 | 0 | 0 | 0 | 310 | 303 |
| Completed | 0 | 0 | 0 | 0 | 288 | 289 |
| Not completed | 0 | 0 | 0 | 0 | 19 | 18 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 8 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 9 | 6 |
| Withdrew: Re-randomized in part 3, however no drug dispensed | 0 | 0 | 0 | 0 | 1 | 0 |
Changes from baseline to Week 4 in mean trough SiSBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiSBP from baseline.
| mmHg | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) |
|---|---|---|---|
| Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement | -15.26 (-17.36 to -13.17) | -15.20 (-17.27 to -13.13) | -11.47 (-13.57 to -9.38) |
Changes from double-blind withdrawal baseline (Week 36) to Week 40 in mean trough SiSBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiSBP from baseline.
| mmHg | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | Placebo in Part 3 (Double-blind Withdrawal) |
|---|---|---|
| Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Unattended Automated Office Blood Pressure Measurement | -1.47 (-2.97 to 0.04) | 4.36 (2.87 to 5.85) |
Changes from baseline to Week 4 in mean trough SiDBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. A negative change indicates a decrease in SiDBP from baseline.
| mmHg | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) |
|---|---|---|---|
| Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement | -10.43 (-11.58 to -9.27) | -10.95 (-12.09 to -9.82) | -6.48 (-7.63 to -5.33) |
ABPM devices were provided to each site by the central blood pressure laboratory. On the first day after all visit assessments were performed, the ABPM device (Mobil-O-Graph NG) was fitted to the participant. The following day (i.e., second day), the participant came back to site to have the ABPM device removed. ABPM data collected over the 24-hours was electronically transferred to the central BP laboratory. Systolic blood pressure and diastolic blood pressure were measured at predetermined times every 20 minutes from 06:00 to 21:59, and every 30 minutes from 22:00 to 05:59. For each participant and at each visit (baseline and Week 4) the 24-hour mean SBP (or DBP) was calculated from the area under the SBP (or DBP) time curve and divided by the time span. A negative change indicates a decrease in 24-hour mean systolic / diastolic blood pressure from baseline.
| mmHg | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) |
|---|---|---|---|
| 24-hour mean systolic blood pressure | -6.73 (-8.20 to -5.26) | -8.44 (-9.88 to -7.00) | -2.55 (-4.00 to -1.10) |
| 24-hour mean diastolic blood pressure | -6.25 (-7.20 to -5.29) | -7.74 (-8.67 to -6.80) | -1.92 (-2.87 to -0.98) |
Changes from double-blind withdrawal (Week 36) to Week 40 in mean trough SiDBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiDBP from baseline.
| mmHg | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | Placebo in Part 3 (Double-blind Withdrawal) |
|---|---|---|
| Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure | -0.52 (-1.54 to 0.50) | 4.67 (3.66 to 5.68) |
ABPM devices were provided to each site by the central blood pressure laboratory. On the first day after all visit assessments were performed, the ABPM device (Mobil-O-Graph NG) was fitted to the participant. The following day (i.e., second day), the participant came back to site to have the ABPM device removed. ABPM data collected over the 24-hours was electronically transferred to the central BP laboratory. Systolic blood pressure and diastolic blood pressure were measured at predetermined times every 20 minutes from 06:00 to 21:59, and every 30 minutes from 22:00 to 05:59. For each participant and at each visit (the double-blind withdrawal baseline \[Week 36\] and the week 40) the 24-hour mean SBP (or DBP) was calculated from the area under the SBP (or DBP) time curve. A negative change indicates a decrease in 24-hour mean systolic / diastolic blood pressure from baseline.
| mmHg | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | Placebo in Part 3 (Double-blind Withdrawal) |
|---|---|---|
| 24-hour mean systolic blood pressure | -0.07 (-1.46 to 1.32) | 6.46 (5.06 to 7.85) |
| 24-hour mean diastolic blood pressure | -0.47 (-1.34 to 0.40) | 6.28 (5.40 to 7.15) |
Collected over Adverse events (AEs) were considered treatment-emergent, if the onset date is between the first intake of treatment up to 30 days after the stop of study treatment. Study treatment was for up to 48 weeks. In Part 1 double-blind (DB) treatment was for 4 weeks. Part 2 single-blind (SB) study treatment was for 32 weeks. In Part 3 double-blind withdrawal (DB-WD) study treatment was for 12 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aprocitentan 12.5 mg in Part 1 (Double-blind) | 1/243 (0.4%) | 8/243 (3.3%) | 16/243 (6.6%) |
| Aprocitentan 25 mg in Part 1 (Double-blind) | 0/245 (0%) | 8/245 (3.3%) | 34/245 (13.9%) |
| Placebo in Part 1 (Double-blind) | 0/242 (0%) | 3/242 (1.2%) | 5/242 (2.1%) |
| Aprocitentan 25 mg in Part 2 (Single-blind) | 9/704 (1.3%) | 82/704 (11.6%) | 95/704 (13.5%) |
| Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | 1/310 (0.3%) | 18/310 (5.8%) | 6/310 (1.9%) |
| Placebo in Part 3 (Double-blind Withdrawal) | 0/303 (0%) | 9/303 (3%) | 4/303 (1.3%) |
| Event | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 2 (Single-blind) | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | Placebo in Part 3 (Double-blind Withdrawal) |
|---|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 2/243 | 0/245 | 1/242 | 14/704 | 4/310 | 2/303 |
| Atrial fibrillationCardiac disorders | 0/243 | 0/245 | 0/242 | 3/704 | 3/310 | 0/303 |
| CellulitisInfections and infestations | 0/243 | 2/245 | 0/242 | 0/704 | 0/310 | 0/303 |
| Angina unstableCardiac disorders | 0/243 | 0/245 | 0/242 | 5/704 | 1/310 | 0/303 |
| PneumoniaInfections and infestations | 1/243 | 1/245 | 0/242 | 2/704 | 2/310 | 0/303 |
| Cardiac failure congestiveCardiac disorders | 0/243 | 0/245 | 0/242 | 3/704 | 0/310 | 0/303 |
| Peritonsillar abscessInfections and infestations | 0/243 | 0/245 | 1/242 | 0/704 | 0/310 | 0/303 |
| Pyelonephritis acuteInfections and infestations | 0/243 | 0/245 | 1/242 | 1/704 | 0/310 | 0/303 |
| SepsisInfections and infestations | 0/243 | 0/245 | 1/242 | 0/704 | 0/310 | 0/303 |
| Ischaemic strokeNervous system disorders | 1/243 | 0/245 | 1/242 | 0/704 | 0/310 | 1/303 |
| Event | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 2 (Single-blind) | Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) | Placebo in Part 3 (Double-blind Withdrawal) |
|---|---|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 16/243 | 34/245 | 5/242 | 95/704 | 6/310 | 4/303 |
| Age, Continuous(years) | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Total |
|---|---|---|---|---|
| Mean | 61.2 ± 10.3 | 61.7 ± 10.4 | 62.2 ± 11.2 | 61.7 ± 10.6 |
| Sex: Female, Male(Participants) | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Total |
|---|---|---|---|---|
| Female | 99 | 98 | 99 | 296 |
| Male | 144 | 145 | 145 | 434 |
| Ethnicity (NIH/OMB)(Participants) | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 28 | 22 | 23 | 73 |
| Not Hispanic or Latino | 213 | 219 | 218 | 650 |
| Unknown or Not Reported | 2 | 2 | 3 | 7 |
| Race (NIH/OMB)(Participants) | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 11 | 14 | 13 | 38 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 28 | 28 | 26 | 82 |
| White | 203 | 200 | 202 | 605 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 3 | 4 |
| Region of Enrollment(participants) | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Total |
|---|---|---|---|---|
| Australia | 8 | 8 | 7 | 23 |
| Belgium | 1 | 3 | 4 | 8 |
| Canada | 8 | 7 | 6 | 21 |
| China | 6 | 11 | 10 | 27 |
| Czechia | 10 | 3 | 15 | 28 |
| Finland | 9 | 5 | 2 | 16 |
| France | 0 | 4 | 3 | 7 |
| Germany | 3 | 6 | 9 | 18 |
| Greece | 5 | 1 | 2 | 8 |
| Hungary | 1 | 4 | 1 | 6 |
| Israel | 5 | 2 | 3 | 10 |
| Italy | 3 | 2 | 0 | 5 |
| Lithuania | 2 | 4 | 4 | 10 |
| Netherlands | 2 | 3 | 3 | 8 |
| Poland | 15 | 16 | 20 | 51 |
| Russia | 61 | 56 | 49 | 166 |
| Spain | 4 | 8 | 6 | 18 |
| Ukraine | 30 | 26 | 30 | 86 |
| United Kingdom | 2 | 0 | 1 | 3 |
| United States | 68 | 74 | 69 | 211 |
| Body Mass Index at Screening Visit(kg/m^2) | Aprocitentan 12.5 mg in Part 1 (Double-blind) | Aprocitentan 25 mg in Part 1 (Double-blind) | Placebo in Part 1 (Double-blind) | Total |
|---|---|---|---|---|
| Mean | 33.6 ± 6.2 | 34.3 ± 6.8 | 33.3 ± 5.6 | 33.7 ± 6.2 |
Showing the first 100 of 159 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in May 2021, 34 months.
Results were first posted in Mar 2023, 1 year 10 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 34 months is above that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aprocitentan
Idorsia Pharmaceuticals Ltd. →